The short version of actin binding fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
== Mechanism == Antivenoms act by binding to and neutralizing venoms. The principle of antivenom is based on that of vaccines, developed by Edward Jenner; however, instead of inducing immunity in the person directly, it is induced in a host animal and the hyperimmunized serum is transfused into the person. The host animals may include horses, donkeys, goats, sheep, rabbits, chickens, llamas, and camels. In addition, opossums are being studied for antivenom production, as unique opossum blood proteins such as lethal toxin neutralizing factor can neutralize snake venoms. Antivenoms for medical use are often preserved as freeze-dried ampoules, but some are available only in liquid form and must be kept refrigerated. They are not immediately inactivated by heat, however, so a minor gap in the cold chain is not disastrous.
Peruvian diplomacy based its principles on continental solidarity (product of Pan-Americanism) and the defense of national sovereignty and integrity, especially the Amazonian ambitions of Brazilian interests and their expansionist advances, which were now related to the Argentines. Evidence of the public condemnation of Peru towards this policy of conquest, by the Brazilians and Argentines against Paraguay, was shown in an edition of the newspaper El Comercio, dated 10/8/1866, which responded to accusations of the anti-Peruvian Argentine press that there was a lack of impartiality in the country due to Peru's sympathy with Paraguay. Given this Peruvian support to Paraguayans, Argentina reacted with anti-Peruvian positions, refusing to be a country a member of the Quadruple Alliance against Spain in the War of the Chincha Islands; In addition, the diplomacy practiced by the Triple Alliance sought to separate the Pacific governments (Chile, Peru, Bolivia and Ecuador) and thus dissolve the Quadruple Alliance. Regarding possible profitable differences, Bolivia was definitely the most vulnerable country, being a priority for Argentine diplomacy. Thus, Argentine and Uruguayan agents tried to seduce the Bolivians, telling them that the scope of the quadruple alliance treaty was not justified, while there were Bolivian territorial claims against the Peruvians and Chileans that the Bolivians still feared would not be able to defend them.
== External links == Cytogenetic Directory Cytogenetics Resources Archived 2017-05-26 at the Wayback Machine Human Cytogenetics - Chromosomes and Karyotypes Association for Genetic Technologists Association of Clinical Cytogeneticists Archived 2000-01-17 at the Wayback Machine Gladwin Medical Blog Archived 2006-11-08 at the Wayback Machine Cytogenetics - Technologies, markets and companies Cytogenetics-methods-and-trouble-shooting Department of Cytogenetics of Wikiversity
== Early life and entry to science == Hofmann was born in Germany but when his father died, his mother returned with her one-year-old son to her family home in Switzerland. The family was business oriented but Klaus was determined to pursue a career in science. He studied steroid chemistry at the Federal Institute of Technology in Zürich (ETH) in the laboratories of Leopold Ružička. Here he developed a friendship with another faculty member, Tadeus Reichstein from whom he learned laboratory technique. For his postdoctoral experience he traveled to the United States to work with Max Bergmann on peptides, an entirely new field for him. From there he migrated across the street to the laboratory of Vincent du Vigneaud where he was introduced to a new vitamin, Biotin.
Sources: en.wikipedia.org
Negroponte examines Dimitri Mobengo Mugianis's long, clandestine career of treating heroin addicts with ibogaine. One of the five segments of "Hallucinogens DMT" (2012), Season 2, Episode 4 of Drugs, Inc. on National Geographic Channel, a former heroin user treats addicts with ibogaine in Canada. He himself used ibogaine to stop his abuse of narcotics. The "Underground Heroin Clinic" segment of "Addiction" (2013). Season 1, episode 7 of the HBO documentary series Vice examines the use of ibogaine to interrupt heroin addiction. The Ibogaine Safari (2014). A documentary by filmmaker Pierre le Roux which investigates the claims of painless withdrawal from opiates such as nyaope/heroin in South Africa by taking several addicts on an adventure "safari" while taking ibogaine. The documentary won the award for 'Best Documentary Short' at the 2014 Canada International Film Festival. Iboga Nights (2014). Directed by David Graham Scott. Dosed. A documentary by Tyler Chandler and Nicholas Meyers. Synopsis- After years of no success with prescription drugs, a suicidal Adrianne seeks help from underground healers with her depression, anxiety, and opioid addiction by utilizing illegal psychedelics like magic mushrooms and iboga. "Synthetic Ibogaine – Natural Tramadol" (2021). This episode of the documentary series Hamilton's Pharmacopeia on Vice on TV follows a struggling local addict to an ibogaine ritual. Lamar Odom Reborn (2022).
== Production == The donkey is considered a seasonal polyestrous animal. However, the latitudinal location of the farm can greatly impact the reproduction cycle. The female is normally pregnant for about 12 months. Donkey milk production differs greatly from that of conventional dairy species, especially in terms of milk supply, which is much more limited. The equid mammary gland has a low capacity (max 2.5 L) and a part of the milk production should be left to the foal. Milking may be carried out two or three hours after separation from the foal. Donkeys should be milked three times a day from 20 to 90 days after foaling. A female produces between 0.5 and 1.3 litres of milk a day for about 6–7 months. The variability of donkey milk production is due to many factors, such as individual milkability, nutrition, genetics and management of reproduction, in addition to milking management. Generally, a donkey farm for milk production is small, and has rarely more than ten heads or so. The largest donkey farm in Europe is found in northern Italy. The Montebaducco donkey farm in Quattro Castella, a comune in Emilia Romagna, Italy, has 800 donkey heads.
Whey protein concentrate: 104 Whole egg: 100 Cow milk: 91 Beef: 80 Casein: 77 Soy: 74 Wheat gluten: 64 By combining different foods it is possible to maximize the score, because the different components favor each other:
Ronnie Kasrils, MK's intelligence chief, warned the Soviet mission that if Saluting October proceeded an SADF counteroffensive was imminent. Gusev overruled the Cuban and MK concerns, and the operation commenced without contingency plans for a South African intervention. The preliminary phase of the new offensive began in August 1987. Eight FAPLA brigades deployed to Tumpo, a region to the east of Cuito Cuanavale in early August, where on Soviet advice they temporarily paused for more supplies and reinforcements. This would prove to be a fatal error. On 14 August, having lost days of precious time, FAPLA resumed its efforts to advance; by then South Africa had launched Operation Moduler to halt the offensive. The bloody campaign that followed entailed a series of engagements known collectively as the Battle of Cuito Cuanavale.
Okazaki fragments Short sequences of nucleotides which are synthesized discontinuously by DNA polymerase and later linked together by DNA ligase to create the lagging strand during DNA replication. Okazaki fragments are the consequence of the unidirectionality of DNA polymerase, which only works in the 5' to 3' direction.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.